natgillin/translations-raw huggingface dataset:
The summary of the opinion of the Committee for Orphan Medicinal Products for Nagalzyme can be found on the Agency’s website ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Nagalzyme kohta on ameti veebilehel: website ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for NexoBrid can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte NexoBridi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Nplate can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Nplate kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Ofev can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Ofevi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Onivyde can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Onivyde kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Opsumit can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Opsumiti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Orfadin can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Orfadini kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation
The summary of the opinion of the Committee for Orphan Medicinal Products for Orphacol can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Orphacoli kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for PhotoBarr can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte PhotoBarri kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Plenadren can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Harvikravimite komitee arvamuse kokkuvõte Plenadreni kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
The summary of the opinion of the Committee for Orphan Medicinal Products for Prialt can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Prialti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Procysbi can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Procysbi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Raxone can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Raxone kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Revestive can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Revestive kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Scenesse can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Scenesse kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Siklos can be found on the Agency’s website ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Siklose kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Sirturo can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Sirturo kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Soliris can be found on the Agency’s website:
Harvikravimite komitee arvamuse kokkuvõte Solirise kohta on ameti veebilehel.
The summary of the opinion of the Committee for Orphan Medicinal Products for Strensiq can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Strensiqi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Strimvelis can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Strimvelise kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Sylvant can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Sylvanti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Tepadina can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Tepadina kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Thalidomide Celgene can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Thalidomide Celgene kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Tobi Podhaler can be found on the Agency’s website ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Tobi Podhaleri kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Torisel can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Harvikravimite komitee arvamuse kokkuvõte Toriseli kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
The summary of the opinion of the Committee for Orphan Medicinal Products for Translarna can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Translarna kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Unituxin can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Unituxini kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Vimizim can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Vimizimi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Volibris can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Volibrise kohta on ameti veebilehel : ema.europa.eu/Find medicine/Human medicines/Rare disease designation..
The summary of the opinion of the Committee for Orphan Medicinal Products for Votubia can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Harvikravimite komitee arvamuse kokkuvõte Votubia kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
The summary of the opinion of the Committee for Orphan Medicinal Products for Vpriv is available on the Agency’s website under EMA website/Find medicine/Human medicines/Rare disease designations.
Harvikravimite komitee arvamuse kokkuvõte Vprivi kohta on ameti veebilehel: EMA website/Find medicine/Human medicines/Rare disease designations.
The summary of the opinion of the Committee for Orphan Medicinal Products for Vyndaqel can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Harvikravimite komitee arvamuse kokkuvõte Vyndaqeli kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Wakix can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Wakixi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Xagrid can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Xagridi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Xaluprine can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Harvikravimite komitee arvamuse kokkuvõte ravimi Xaluprine kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
The summary of the opinion of the Committee for Orphan Medicinal Products for Yondelis can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation
Harvikravimite komitee arvamuse kokkuvõtted Yondelise kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation
The summary of the opinion of the Committee for Orphan Medicinal Products for Zalmoxis can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Zalmoxise kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The superiority of Toujeo over insulin glargine 100 units/ml in lowering the risk of confirmed nocturnal hypoglycemia was shown in patients with type 2 diabetes treated with basal insulin in combination with either non-insulin anti-hyperglycaemic medicinal product (18% risk reduction) or mealtime insulin (21% risk reduction) during the period from week 9 to end of study period.
Toujeo paremust võrreldes 100 ühikut/ml sisaldava glargiin-insuliiniga öise hüpoglükeemia riski vähendamisel tõestati 2. tüüpi diabeediga patsientidel, kes said ravi basaalinsuliiniga kombinatsioonis teiste vere glükoosisisaldust vähendavate ainetega (riski langus 18%) või söögi ajal manustatava insuliiniga (riski langus 21%) ajavahemikus alates 9. uuringunädalast kuni uuringu lõpuni.
The supplied oral dosing pipette should not be used for any other medicinal products.
Ravimiga kaasasolevat suukaudseks manustamiseks mõeldud pipetti ei ole lubatud kasutada ühegi teise ravimi jaoks.
The supplied solvent is used to dilute the concentrate to the correct dilution to allow for optimisation of the preferred injection volumes for fish of widely varying body weights.
Kaasasolev lahusti on kontsentraadi lahustamiseks, et saavutada õige lahjendus, mis vastab kalade keskmisele kehamassile ja lubab optimeerida ravimi doosi kaladel, kelle kehamass võib suuresti varieeruda.
The supra- therapeutic doses are adequate to represent quinidine exposure increases due to drug-drug interactions and organ dysfunctions.
Antud uuringus kasutatud terapeutilistest annustest suuremad annused kirjeldavad võimalikku QT-intervalli pikenemist ka ravimite koostoimetest tingitud kinidiini plasmatasemete suurenemise korral või organpuudulikkusega patsientidel.
The surface antigens are also ‘adsorbed’.
Pinnaantigeenid on ka adsorbeeritud.
The surface antigens are produced by a method known as ‘recombinant DNA technology’: they are made by a yeast that has received a gene (DNA), which makes it able to produce the proteins.
Ravimis Fendrix sisalduvaid pinnaantigeene valmistatakse rekombinant-DNA-tehnika abil: neid toodab pärm, millele on lisatud nende proteiinide tootmist võimaldav geen (DNA).
The surface antigens in HBVaxPro are produced by a method known as ‘recombinant DNA technology’: they are made by a yeast that has received a gene (DNA), which makes it able to produce the proteins.
HBVaxPros sisalduvaid pinnaantigeene valmistatakse rekombinant-DNA-tehnika abil: neid toodab pärm, millele on lisatud nende valkude teket võimaldav geen (DNA).
The surface antigens of the hepatitis B virus are produced
B-hepatiidi viiruse pinnaantigeene valmistatakse
The surface antigens of the hepatitis B virus are produced by a method known as ‘recombinant DNA technology’: they are made by a yeast that has received a gene (DNA), which makes it able to produce the proteins.
B-hepatiidi pinnaantigeene toodetakse rekombinant- DNA-tehnika meetodil: neid toodab pärm, millesse on viidud valkude teket võimaldav geen (DNA).
The surface antigens of the hepatitis B virus are produced by a method known as ‘recombinant DNA technology’: they are made by a yeast that has received a gene (DNA), which makes it able to produce the proteins.
B-hepatiidi viiruse pinnaantigeene valmistatakse rekombinant-DNA- tehnika abil: neid toodab pärm, millele on lisatud nende valkude teket võimaldav geen (DNA).
The surface antigens of the hepatitis B virus are produced by a method known as ‘recombinant DNA technology’: they are made by a yeast that has received a gene (DNA), which makes it able to produce the proteins.
B-hepatiidi viiruse pinnaantigeene valmistatakse rekombinant-DNA-tehnika abil: neid toodavad pärmirakud, millesse on viidud valkude teket võimaldav geen (DNA).
The surface dose rates and the accumulated dose depend on many factors.
Pinna doosikiirgus ja akumuleerunud kiirgusdoos sõltuvad paljudest teguritest.
The surgeon will apply EVARREST during your operation.
Operatsiooni ajal paigaldab EVARREST’i teie kirurg.
The surgical checklist to be completed at the operating theatre immediately prior to the first incision confirming the right patient, the right product, the right side of the implantation, and the type of biological membrane and fibrin sealant to be used in the procedure.
vahetult enne esimest sisselõiget operatsiooniruumis järgitav kirurgi meeldetuletusloend, millega kontrollitakse patsiendi, ravimi ja implanteerimispoole õigsust ning protseduuris kasutatava bioloogilise membraani ja fibriinliimi tüüp;
The surveillance programme/registry should prompt doctors to report adverse reactions
Järelevalveprogrammis/registris peaks olema ette nähtud, et arstid teatavad kõrvaltoimetest.
The surveillance programme/registry should prompt doctors to report adverse reactions.
Järelevalveprogrammis/registris peaks olema ette nähtud, et arstid teatavad kõrvaltoimetest.
The survival curves indicated that, by the end of the entire follow-up period, patients in the PhotoBarr PDT + OM group had a 83% chance of being cancer-free as compared to a 53% chance for patients in the OM only group.
Elulemuse kõverad näitasid, et jälgimisperioodi lõpuks oli PhotoBarr’i PDT+OM gruppi kuuluvatel patsientidel 83%-line võimalus mitte vähki haigestuda võrrelduna 53%-ga ainult OM-i grupis.
The survival rate was 93.7% in the TAC arm and 91.4% in the FAC arm, at the 8-year follow-up timepoint, and 91.3% in the TAC arm and 89% in the FAC arm, at the 10-year follow-up timepoint.
Ajahetkel, kui järelkontrolliperiood oli kestnud 8 aastat, oli elulemuse määr TAC ravihaaras 93,7% ja FAC ravihaaras 91,4% ning ajahetkel 10 aastat oli see TAC ravihaaras 91,3% ja FAC ravihaaras 89%.
The suspended product will be yellow and opaque. (See Figure C)
Suspendeerunud preparaat näib kollane ja tuhm. (Vt Joonis C)
The suspension can be drawn up with a syringe or swallowed directly by the patient.
Suspensiooni võib patsiendi jaoks tõmmata süstlasse või anda juua otse tassist.
The suspension can be given using either of the two measuring syringes provided in the package (depending on weight of dog).
Suspensiooni võib manustada pakendis oleva kahe annustamissüstla abil.
The suspension can be given using either the drop dispenser of the bottle (for very small breeds) or the measuring syringe provided in the package.
Suspensiooni võib manustada kas pudeli tilgapipetiga (väga väikestel tõugudel) või pakendis oleva mõõtesüstlaga.
The suspension can be given using the measuring syringes provided in the package.
Suspensiooni võib anda doseerimissüstla abil, mis on lisatud pakendile.
The suspension can be given using the measuring syringes provided in the package.
Suspensiooni võib manustada pakendis oleva mõõtesüstlaga.
The suspension can be given using the Melosus measuring syringe provided in the package.
Suspensiooni võib manustada pakendis oleva Melosusi mõõtesüstlaga.
The suspension could be administered using the smallest syringe for dogs less than 7 kg body weight (one graduation corresponding to 0.5 kg of body weight) or the largest syringe for dogs over than 7 kg body weight (one graduation corresponding to 2.5 kg of body weight).
Väiksematele koertele – alla 7 kg – võib suspensiooni manustada kasutades väikseimat süstalt (gradueeringu üks vahemik vastab 0,5 kg kehamassile) ja suurematel koertele (üle 7 kg) suure süstlaga (gradueeringu üks vahemik vastab 2,5 kg kehamassile).
The suspension has a slightly acidic taste.
Suspensioonil on hapukas maitse.
The suspension has to be given with the measuring syringe provided in the package of the 30 and 150 ml pack size or with one of the two measuring syringes provided in the package of the 10 ml pack size.
Suspensiooni tuleb manustada 30 ml ja 150 ml pakendites olevate annustamissüstalde abil või ühega kahest annustamissüstlast, mis on lisatud 10 ml pakendile.
The suspension is a translucent to off white opalescent suspension, which may sediment slightly.
Suspensioon on läbipaistev kuni valkjas opalestseeruv suspensioon, milles võib olla vähene sade.
The suspension is a translucent to off white opalescent suspension, which may sediment slightly.
Suspensioon on poolläbipaistev kuni valkjas opalestseeruv suspensioon, milles võib olla kerge sade.
The suspension is administered in the patient’s mouth with an oral syringe without dilution.
Suspensiooni manustatakse lahjendamata kujul patsiendi suhu suusüstlaga.
The suspension is clear to opalescent.
Suspensioon on läbipaistev kuni küütlev.
The suspension is cloudy, white and aqueous.
Hägune valge vesisuspensioon.
The suspension is cloudy, white and aqueous.
Hägune, valge vesisuspensioon.
The suspension is contained in type I flint glass cartridges, sealed with halobutyl disc seals and plunger heads and secured with aluminium seals.
Suspensioon on I tüüpi flintklaasist kolbampullis, mis on kinni pitseeritud butüülist või halobutüülist diski ja kolvi kaanega ning mida kaitseb alumiiniumplomm.
The suspension is contained in type I flint glass cartridges, sealed with halobutyl disc seals and plunger heads and secured with aluminium seals.
Suspensioon paikneb I tüüpi flintklaasist kolbampullis, mis on kinni pitseeritud butüülist või halobutüülist diski ja kolvi kaanega ning mida kaitseb alumiiniumplomm.
The suspension is given using the Loxicom measuring syringe provided in the package.
Suspesiooni manustamiseks kasutada pakendis olevat Loxicomi mõõtesüstalt.
The suspension is opalescent and homogeneous.
Suspensioon on opalestsentne ja homogeenne.
The suspension is white to off-white in colour.
Suspensioon on valget või tuhmvalget värvi.
The suspension must be injected immediately after mixing the powder and the solvent.
Suspensioon tuleb süstida koheselt pärast pulbri ja lahusti segamist.
The suspension must be taken straight away.
Valmis suspensiooni tuleb võtta koheselt.
The suspension of the marketing authorisation was lifted on 12 March 2014.
Müügiloa piirang kaotati 12. märtsil 2014. aastal.
The suspension powder is pale yellow with a citrus flavour.
Suspensioonipulber on kahvatukollane ja tsitruselõhnaga.
The suspension should be administered immediately after complete disintegration of the tablet(s).
Lahus tuleb manustada koheselt peale tableti täielikku lahustumist vedelikus.
The suspension should be allowed up to 30 minutes prior to administration to reach room temperature (20 °C – 25 °C).
Valmis suspensiooniga süstlal tuleb lasta enne manustamist kuni 30 minuti jooksul soojeneda ligikaudu temperatuurini 20 °C…25 °C.
The suspension should be given using the Inflacam measuring syringe provided in the package.
Suspensiooni tuleks manustada pakendis oleva mõõtesüstlaga.
The suspension should be given using the Rheumocam measuring syringe provided in the package.
Suspensiooni tuleks manustada pakendis oleva mõõtesüstlaga.
The suspension, supplied in a bottle is whitish.
Pudelis turustatav suspensioon on valkjas.
The sustained viral response achieved with 16 weeks of treatment and with 24 weeks of treatment was also examined in a retrospective subgroup analysis of patients who were HCV RNA negative by week 4 and had a LVL at baseline (see Table 16).
4. nädalaks HCV RNA negatiivsete ja ravieelselt madala vireemia tasemega (LVL) patsientide retrospektiivses alagrupi analüüsis uuriti ka 16-nädalase ja 24-nädalase raviga saavutatud püsivat viroloogilist ravivastust (vt tabel 16).
The SVR rates in subjects randomized to receive ribavirin dose reduction and randomized to receive erythropoietin were comparable.
Patsientidel, keda randomiseeriti saama vähendatud annuses ribaviriini ja keda randomiseeriti saama erütropoetiini, olid SVR-i määrad sarnased.